Trial reportCardiovascular diabetology2012
Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?
Trial report in Cardiovascular diabetology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 47 citations in OpenAlex.
- Metformin Alters Exercise Training Induced Blood Pressure and Aortic Waveform Adaptations in Adults at Risk for Metabolic Syndrome.Journal of clinical hypertension (Greenwich, Conn.) · 2026Trial
- Trial
- Metformin and the Liver: Unlocking the Full Therapeutic Potential.Metabolites · 2024Review
- Effects of metformin on arterial elasticity and pro-inflammatory markers in black diabetes patients.Health SA = SA Gesondheid · 2024Article
- Role of the AMPK/SIRT1 pathway in non‑alcoholic fatty liver disease (Review).Molecular medicine reports · 2023Review
- Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?Biology · 2022Review
- Association of IL-10 and CRP with Pulse Wave Velocity in Patients with Abdominal Aortic Aneurysm.Journal of clinical medicine · 2022Article
- The Association Between FGF21 and Diabetic Erectile Dysfunction: Evidence from Clinical and Animal Studies.Frontiers in endocrinology · 2022Article
- Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis.World journal of diabetes · 2021Article
- Treating Arterial Ageing in Patients with Diabetes: From Mechanisms to Effective Drugs.International journal of molecular sciences · 2021Review
- Article
- Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease.Endocrinology and metabolism (Seoul, Korea) · 2018Review
- Metformin and metabolic diseases: a focus on hepatic aspects.Frontiers of medicine · 2015Review
- Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease.World journal of hepatology · 2015Review
- Therapeutic effects of globular adiponectin in diabetic rats with nonalcoholic fatty liver disease.World journal of gastroenterology · 2014Article
- Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?Cardiovascular diabetology · 2014Review
- Insulin sensitizers for the treatment of non-alcoholic fatty liver disease.World journal of hepatology · 2014Review
- Nonalcoholic fatty pancreatic disease and cardio-metabolic risk: is there is a place for obstructive sleep apnea?Cardiovascular diabetology · 2014Review
- CNX-012-570, a direct AMPK activator provides strong glycemic and lipid control along with significant reduction in body weight; studies from both diet-induced obese mice and db/db mice models.Cardiovascular diabetology · 2014Article
- Metformin suppresses expression of the selenoprotein P gene via an AMP-activated kinase (AMPK)/FoxO3a pathway in H4IIEC3 hepatocytes.The Journal of biological chemistry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInsulin resistance (IR) is the major driving force behind development and progression of atherosclerosis in patients with nonalcoholic fatty liver disease (NAFLD). Therefore, correction of IR is a relevant therapeutic target.We performed the current trial to evaluate whether 12- month metformin therapy improves vascular stiffness in patients with NAFLD and to assess if this improvement is associated with change in glucose control, insulin resistance or circulating adiponectin.
methodsIn randomized, placebo controlled study, 63 patients with NAFLD were assigned to one of two groups: Group 1 received daily metformin; Group 2 received placebo. Central aortic augmentation index (AI) was performed using SphygmoCor (version 7.1, AtCor Medical, Sydney, Australia) at baseline, at 4-and 12-month treatment period. Metabolic parameters, insulin resistance markers and serum adiponectin levels were determined.
resultsIn placebo group: AI did not improve during the treatment period. Liver function and adiponectin levels did not change during the study.In multiple linear regression analysis, the independent predictors of arterial stiffness improvement were metformin treatment and increase in circulating adiponectin levels.Among metformin treated patients: AI decreased significantly during the study. ALP and ALT decreased during initial 4-month treatment period, however raised to the pretreatment levels after 12 months. Serum adiponectin level tended to increase during treatment period with metformin.
conclusionsMetformin treatment was associated with significant decrease in AI during one year treatment in NAFLD patients. These beneficial vascular effects was associated with exposure to metformin per se as well as change in adiponectin levels suggesting that metformin may mediate its vascular effects via glycemic control-independent mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.